Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002928|
Recruitment Status : Completed
First Posted : March 12, 2004
Last Update Posted : June 26, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or progressive advanced epithelial ovarian cancer following previous paclitaxel.
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer||Drug: paclitaxel||Phase 2|
OBJECTIVES: I. Evaluate the activity of paclitaxel when administered on a weekly schedule to patients with advanced ovarian cancer who have failed paclitaxel on a 3 or 24 hour infusion schedule. II. Evaluate the toxic effects of paclitaxel when administered on a weekly schedule in this patient population. III. Correlate response with quality of life outcomes, including symptom distress, performance status, and global quality of life.
OUTLINE: This is a single center, open label study. Paclitaxel is administered intravenously every week as a 1 hour infusion. Patients receive prophylactic anti-allergy premedication prior to paclitaxel.
PROJECTED ACCRUAL: 25-30 patients accrued per year.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Phase II Trial of Paclitaxel Administered Weekly in Patients With Advanced Ovarian Cancer|
|Study Start Date :||January 1997|
|Primary Completion Date :||August 2001|
|Study Completion Date :||August 2001|
U.S. FDA Resources
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002928
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10021|
|Study Chair:||Carol Aghajanian, MD||Memorial Sloan Kettering Cancer Center|